REVIEW article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Blood-based Epigenetic Biomarkers in Rheumatoid arthritis: Current Knowledge and Future Perspectives
Provisionally accepted
- Wydział Medyczny, Uniwersytet Rzeszowski Instytut Nauk Medycznych, Rzeszow, Poland
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that leads to progressive joint destruction, extra-articular manifestations, disability, and increased mortality. Early detection, particularly in seronegative patients, remains challenging because current diagnostic criteria based on joint involvement, serology, and acute-phase reactants may fail to identify disease at its earliest stages. Epigenetic mechanisms, including DNA and RNA methylation, histone modifications, and non-coding RNAs (ncRNAs), provide a dynamic interface between genetic predisposition and environmental triggers in RA pathogenesis. Peripheral blood (plasma, serum, and cellular fractions) is an accessible, minimally invasive source for monitoring systemic molecular alterations over time. To capture the latest evidence, we performed a structured literature search using curated keywords covering RA, epigenetic mechanisms, DNA and RNA methylation, m6A, histone modifications, miRNAs, lncRNAs, circRNAs, and blood-based fractions (peripheral blood mononuclear cells (PBMCs), plasma, serum, whole blood). Emerging data indicate that blood-based epigenetic signatures not only reflect disease activity but also hold promise as prognostic biomarkers, predictors of treatment response, and tools for personalized therapeutic strategies. In this review, we synthesize current knowledge on blood-based epigenetic alterations in RA, focusing on DNA methylation, histone modifications, and multiple classes of ncRNAs, including less widely studied species such as piRNAs, snoRNAs, Y-RNAs, snRNAs, and tRNA-derived fragments, with an emphasis on studies published between 2020 and 2025. We highlight the translational potential of multilayered epigenetic signatures as innovative diagnostic and prognostic tools that could advance early detection and guide precision-medicine approaches in RA.
Keywords: DNA Methylation, epigenetics, histonemodifications, non-coding RNAs, Peripheral blood biomarkers, Rheumatoid arthritis, RNA methylation
Received: 25 Nov 2025; Accepted: 16 Jan 2026.
Copyright: © 2026 Mołoń, Kubis, Żurawska and Cieśla. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Agnieszka Mołoń
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.